Adverse Drug Reactions During COVID-19 Treatment

Pınar METBULUT, (Ankara Şehir Hastanesi)
Emine DİBEK MISIRLIOĞLU (Sağlık Bilimleri Üniversitesi, Ankara Şehir Çocuk Hastanesi, Çocuk Alerji ve İmmünoloji AD, Ankara, Türkiye)
Türkiye Çocuk Hastalıkları Dergisi
0 0
Yıl: 2020 Cilt: 14 Sayı: EK SAYI 1 Sayfa Aralığı: 65 - 71 Metin Dili: İngilizce DOI: 10.12956/tchd.757723 İndeks Tarihi: 30-07-2021

Adverse Drug Reactions During COVID-19 Treatment

Öz:
Adverse drug reactions are unintented and harmful reactions to drugs. Coronavirus disease 2019 (Covid-19) has beenwidely spread. Although many drugs are used in the treatment of COVID-19, there is still no specific treatment withproven reliability and effectiveness and there are many studies to find effective treatment. Attention should be takenregarding the properties, interactions and undesired drug reactions of drugs used in the treatment of COVID-19. Theaim of this review is to draw attention to adverse drug reactions of the drugs that are being used in COVID-19 treatment.
Anahtar Kelime:

COVID-19 Tedavisinde İstenmeyen İlaç Reaksiyonları

Öz:
stenmeyen ilaç reaksiyonları ilaç kullanımında ortaya çıkan istenmeyen, zararlı etkilerdir. Coronavirus hastalığı 2019 (Covid-19) tüm dünyaya yayılmıştır. COVID-19 tedavisinde birçok ilaç kullanılmasına karşın, güvenilirliği ve etkinliği kanıtlanmış spesifik bir tedavi henüz yoktur ve etkili tedaviyi bulmak için çalışmalar devam etmektedir. COVID-19 tedavisinde kullanılan ilaçların özelliklerine, etkileşimlerine ve istenmeyen ilaç reaksiyonlarına dikkat edilmelidir. Bu derlemenin amacı COVID-19 tedavisinde kullanılan ilaçların istenmeyen ilaç reaksiyonlarına dikkat çekmektir.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
  • 1. Dona I, Salas M, Perez-Sanchez NI, Aguilar C, Torres MJ. Phenotypes and Natural Evolution of Drug Hypersensitivity. Curr Treat Options Allergy 2019;6:27-41.
  • 2. Dona I, Caubet JC, Brockow K, Doyle M, Moreno E, Terreehorst I, et al. An EAACI task force report: recognising the potential of the primary care physician in the diagnosis and management of drug hypersensitivity. Clin Transl Allergy. 2018 May 10;8:16. doi: 10.1186/s13601-018-0202-2.
  • 3. Fernandez J, Dona I. Diagnosing and managing patients with drug hypersensitivity. Expert Rev Clin Immunol 2018:14:29-41
  • 4. Muraro A, Lemanske R, Castells M, Torres MJ, Khan D, Simon HU, et al. Precision Medicine in Allergic Disease-Food Allergy, Drug Allergy , and Anaphylaxis- PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma and Immunology. Allergy 2017;72:1006-21
  • 5. Demoly P, Adkinson NF, Brockow K, Castells M, Chiriac AM, Greenberger PA, et al. International Consensus on drug allergy. Allergy 2014;69:420-37.
  • 6. Gomes ER, Brockow K, Kuyucu S, Saretta F, Mori F, BlancaLopez N, et al. Drug hypersensitivity in children: report from the pediatric task force of the EAACI Drug Allergy Interest Group. Allergy 2016:149-61.
  • 7. Hausmann O. Drug Allergy. Middleton’s Allergy Principles and Practice. 8th edition. Philadelphia. Elsevier 2014:1274-1295
  • 8. https://covid19bilgi.saglik.gov.tr/depo/rehberler/COVID-19_ Rehberi.pdf
  • 9. Food and Drug Administration (FDA). Coronavirus disease 2019 (COVID-19). 2020.https://www.fda.gov/emergencypreparedness-and response/counterterrorism-and-emergingthreats/coronavirus-disease-2019-covid-19.
  • 10. Smith T, Bushek J, Prosser T, COVID-19 Drug Theraphy. Elsevier 2020.
  • 11. Juurlink D, Safety consideration with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection. CMAJ 2020.
  • 12. https://khgmstokyonetimidb.saglik.gov.tr/TR,64702/ hidroksiklorokin-sulfat-200-mg-film-tablet---covid-19-sars-cov2- enfeksiyonu-tedavisinde-kullanilacak-ilaclara-iliskin-bilgilendirme. html
  • 13. Naksuk N, Lazar S, Peeraphatdit TB. Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol. Eur Heart J Acute Cardiovasc Care. 2020;9:215-21.
  • 14. Page RL, O’Bryant CL, Cheng D, Dow TJ, Ky B, Stein CM, et al. Drugs that may cause or exacerbate heart failure. Circulation 2016; 134: e32–e69.
  • 15. Lane JCE, Weaver J, Kostka K, et al. Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid widespread use for COVID-19: a multinational, network cohort and selfcontrolled case series study. medRxiv 2020. doi.org/10.1101/20 20.04.08.20054551.
  • 16. Saleh M, Gabriels J, Chang D, Kim BS, Mansoor A, Mahmood E, et al. The Effect of Chloroquine, Hydroxychloroquine and Azithromycin on the Corrected QT Interval in Patients with SARSCoV-2 Infection. Circ Arrhythm Electrophysiol. 2020 Apr 29. Doi :10.1161/CIRCEP.120.008662. [Epub ahead of print]
  • 17. Bessière F, Roccia H, Delinière A, Charrière R, Chevalier P, Argaud L, et al. Assessment of QT Intervals in a case series of patients with coronavirus disease 2019 (COVID-19) infection treated with hydroxychloroquine alone or in combination with azithromycin in an intensive care unit. JAMA Cardiol 2020; e201787. doi: 10.1001/ jamacardio.2020.1787.
  • 18. Mercuro NJ, Yen CF, Shim DJ, Maher TR, McCoy CM, Zimetbaum PJ, et al. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus 2019 (COVID-19) infection. JAMA Cardiol 2020;e201834. doi:10. 1001/ jamacardio.2020.1834.
  • 19. Asli R, Abdullah MS, Chong PL,Metussin D, Momin RN, Mani BI, et al. Case Report: Right Bundle Branch Block and QTc Prolongation in a Patient with Novel Coronavirus Disease (COVID-19) Treated with Hydroxychloroquine. Am J Trop Med Hyg 2020 May 7. doi: 10.4269/ajtmh.20-0376. [Epub ahead of print]
  • 20. Yusuf IH, Sharma S, Luqmani R, Downes SM. Hydroxychloroquine retinopathy. Eye (Lond) 2017;31:828-45.
  • 21. Furst DE, Lindsley H, Baethge B, Botstein GR, Caldwell J, Dietz F, et al. Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis: a randomized, double-blind six-week trial with eigh- teen-week extension. Arthritis Rheum 1999;42:357–65.
  • 22. Mohammad S, Clowse MEB, Eudy AM, Schreiber LGC. Examination of hydroxychloroquine use and hemolytic anemia in G6PDHdeficient patients. Arthritis Care Res (Hoboken) 2018;70:481-5.
  • 23. http://products.sanofi.ca/en/plaquenil.pdf
  • 24. Randhawa A, Wylie G. A case of an acute cutaneous drug reaction with hydroxychloroquine. Scott Med J 2018;63:91-4.
  • 25. Schwartz RA, Janniger CK. Generalized pustular figurate erythema a newly delineated severe cutaneous drug reaction linked with hyroxychloroquine. Dermatol Ther 2020:e13380. doi: 10.1111/ dth.13380.
  • 26. Kutlu Ö, Metin A. A case of exacerbation of psoriasis after oseltamivir and hydroxychloroquine in a patient with COVID-19: Will cases of psoriasis increase after COVID-19 pandemic?. Dermatol Ther 2020 Apr 7:e13383. doi: 10.1111/dth.13383. 27. https://dosyamerkez.saglik.gov.tr/Eklenti/36979,covid---19- tedavisinde-kullanilan-ilaclar---ilac-etkilesimleripdf.pdf?0
  • 28. Smith C, Egunsola O, Choonara I, Kotecha S, Jacqz-Aigrain E, Sammons H. Use and safety of azithromycin in neaonates: a systematic review. BMJ 2015;5:e008194. doi: 10.1136/ bmjopen-2015-008194.
  • 29. Barni S, Butti D, Mori F, Pucci N, Rossi ME, Cianferoni A, et al. Azithromycin is more allergenic than clarithromycin in children with suspected hypersensitivity reaction to macrolides. J Investig Allergol Clin Immunol 2015;25:128-32.
  • 30. Cvetkovic RS, Goa KL. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs 2003;63:769-802.
  • 31. e XT, Luo YL, Xia SC, Sun QF, Ding JG, Zhou Y, et al. Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019. Eur Rev Med Pharmacol Sci 2020;24:3390-6.
  • 32. Du YX, Chen XP. Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection. Clin Pharmacol Ther 2020 Apr 4. doi: 10.1002/cpt.1844.
  • 33. Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering (Beijing) 2020 Mar 18. doi: 10.1016/j. eng.2020.03.007.
  • 34. Mitha E, Krivan G, Jacobs F, Nagler A, Alrabaa S, Mykietiuk A, et al. Safety, Resistance, and Efficacy Results from a Phase IIIb Study of Conventional- and Double-Dose Oseltamivir Regimens for Treatment of Influenza in Immunocompromised Patients. Infect Dis Ther 2019;8:613-26.
  • 35. Dalvi PS, Singh A, Trivedi HR, Mistry SD, Vyas BR. Adverse drug reaction profile of oseltamivir in children. J Pharmacol Pharmacother 2011;2:100-3.
  • 36. Soyer O, Demir S, Bilginer Y, Batu ED, Sonmez HE, Arıcı ZS, et al. Severe hypersensitivity reactions to biological drugs in children with rheumatic diseases. Pediatr Allergy Immunol 2019;30:833-40
  • 37. Brucato A, Imazio M, Gattorno M, Lazaros G, Maestroni S, Carraro M, et al. Effect of Anakinra on Recurrent Pericarditis Among Patients With Colchicine Resistance and Corticosteroid Dependence: The AIRTRIP Randomized Clinical Trial. JAMA 2016;316:1906-12.
  • 38. Aguiar CL, Pan M, Adams A. Anaphylaxis to anakinra in a pediatric patient with systemic juvenile idiopathic arthritis successfully treated with canakinumab: a case-based review. Clin Rheumatol 2015;34:1821-4.
APA metbulut p, Dibek Mısırlıoğlu E (2020). Adverse Drug Reactions During COVID-19 Treatment. , 65 - 71. 10.12956/tchd.757723
Chicago metbulut pınar,Dibek Mısırlıoğlu Emine Adverse Drug Reactions During COVID-19 Treatment. (2020): 65 - 71. 10.12956/tchd.757723
MLA metbulut pınar,Dibek Mısırlıoğlu Emine Adverse Drug Reactions During COVID-19 Treatment. , 2020, ss.65 - 71. 10.12956/tchd.757723
AMA metbulut p,Dibek Mısırlıoğlu E Adverse Drug Reactions During COVID-19 Treatment. . 2020; 65 - 71. 10.12956/tchd.757723
Vancouver metbulut p,Dibek Mısırlıoğlu E Adverse Drug Reactions During COVID-19 Treatment. . 2020; 65 - 71. 10.12956/tchd.757723
IEEE metbulut p,Dibek Mısırlıoğlu E "Adverse Drug Reactions During COVID-19 Treatment." , ss.65 - 71, 2020. 10.12956/tchd.757723
ISNAD metbulut, pınar - Dibek Mısırlıoğlu, Emine. "Adverse Drug Reactions During COVID-19 Treatment". (2020), 65-71. https://doi.org/10.12956/tchd.757723
APA metbulut p, Dibek Mısırlıoğlu E (2020). Adverse Drug Reactions During COVID-19 Treatment. Türkiye Çocuk Hastalıkları Dergisi, 14(EK SAYI 1), 65 - 71. 10.12956/tchd.757723
Chicago metbulut pınar,Dibek Mısırlıoğlu Emine Adverse Drug Reactions During COVID-19 Treatment. Türkiye Çocuk Hastalıkları Dergisi 14, no.EK SAYI 1 (2020): 65 - 71. 10.12956/tchd.757723
MLA metbulut pınar,Dibek Mısırlıoğlu Emine Adverse Drug Reactions During COVID-19 Treatment. Türkiye Çocuk Hastalıkları Dergisi, vol.14, no.EK SAYI 1, 2020, ss.65 - 71. 10.12956/tchd.757723
AMA metbulut p,Dibek Mısırlıoğlu E Adverse Drug Reactions During COVID-19 Treatment. Türkiye Çocuk Hastalıkları Dergisi. 2020; 14(EK SAYI 1): 65 - 71. 10.12956/tchd.757723
Vancouver metbulut p,Dibek Mısırlıoğlu E Adverse Drug Reactions During COVID-19 Treatment. Türkiye Çocuk Hastalıkları Dergisi. 2020; 14(EK SAYI 1): 65 - 71. 10.12956/tchd.757723
IEEE metbulut p,Dibek Mısırlıoğlu E "Adverse Drug Reactions During COVID-19 Treatment." Türkiye Çocuk Hastalıkları Dergisi, 14, ss.65 - 71, 2020. 10.12956/tchd.757723
ISNAD metbulut, pınar - Dibek Mısırlıoğlu, Emine. "Adverse Drug Reactions During COVID-19 Treatment". Türkiye Çocuk Hastalıkları Dergisi 14/EK SAYI 1 (2020), 65-71. https://doi.org/10.12956/tchd.757723
Sayfa Oluşturulma Tarihi
17-04-2024 20:52

İLETİŞİM

TÜBİTAK ULAKBİM TR Dizin

Yüzüncüyıl, İşçi Blokları Mahallesi

Muhsin Yazıcıoğlu Caddesi No:51/C

06530 Çankaya / ANKARA +90 (312) 298 92 00

trdizin@tubitak.gov.tr

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © Tüm Hakları Saklıdır. Gizlilik Politikası Kullanım Şartları